Transgene Quote - TNG

	Real-time Prices	Level 2
Australian Stock Exchange

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.766

Bid

0.754

Offer

0.771

Volume

21,482

0.758 Day's Range 0.777

0.743 52 Week Range 1.52

Market Cap

77.253M

Previous Close

0.762

Open

0.777

Last Trade

0.766

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

35,179

Shares Outstanding

100,852,742

Dividend Yield

PE Ratio

-3.48

Earnings Per Share (EPS)

-0.22

Revenue

7.9M

Net Profit

-22.33M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.transgene.fr

Headquarters

Illkirch-graffenstaden, Bas-rhin, Fra

Founded

Transgene SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker TNG. The last closing price for Transgene was 0.76 €. Over the last year, Transgene shares have traded in a share price range of 0.743 € to 1.52 €.

Transgene currently has 100,852,742 shares in issue. The market capitalisation of Transgene is 76.85 € million. Transgene has a price to earnings ratio (PE ratio) of -3.48.

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data...

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Top line data show that the randomized...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.006	0.789473684211	0.76	0.8	0.743	20065	0.77286698	DE
4	-0.084	-9.88235294118	0.85	0.964	0.743	33575	0.85601527	DE
12	-0.352	-31.4847942755	1.118	1.204	0.743	35179	0.97546134	DE
26	-0.484	-38.72	1.25	1.35	0.743	30331	1.05079532	DE
52	-0.688	-47.3177441541	1.454	1.52	0.743	29933	1.17119193	DE
156	-1.884	-71.0943396226	2.65	2.78	0.743	35231	1.85690435	DE
260	-1.034	-57.4444444444	1.8	3.15	0.743	74406	1.98314908	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALNEVNeovacs	0.0002 € (100.00%)	23.96M
ALEUPEuroplasma	0.0615 € (97.75%)	12.45M
ALGAUGaussin	0.08 € (90.48%)	3.38M
ATOAtos SE	1.013 € (79.99%)	42.94M
ALTAILighton	16.79 € (44.49%)	188.11k
BIDSGascogne DS	0.0006 € (-72.73%)	197.99k
EMGDSEuromedis DS	0.0004 € (-50.00%)	34.36k
MLMAZMazaro NV	2.16 € (-28.00%)	500
MLIMLImalliance	0.33 € (-23.26%)	9.9k
GNROGeNeuro SA	0.0562 € (-14.85%)	116.8k
ATOAtos SE	1.013 € (79.99%)	42.94M
BCPBanco Comercial Portugues SA	0.444 € (-0.22%)	33.65M
ALNEVNeovacs	0.0002 € (100.00%)	23.96M
ALDRVDrone Volt	0.0036 € (2.86%)	23.3M
ALNRGEnergisme SA	0.0055 € (-3.51%)	12.47M